Endo Pharmaceuticals entered two research collaborations for pain and cancer treatments. The company will partner with Harvard University on a pain drug-delivery technique. The method, which was discovered at the university, reportedly targets pain-sensing neurons without affecting motor neurons.
This agreement with Harvard gives Endo exclusive, worldwide rights to the technology. Endo will be responsible for development and commercialization of any drug candidates discovered under the agreement. This is Endo’s second deal this year related to pain. In January, Endo entered a merger agreement with Indevus valued at $637 million to pad its pain-management business.
The second agreement, with Aurigene Discovery Technologies, is a three-year collaboration to discover anticancer agents. Aurigene will be responsible for all discovery and preclinical research activities, while Endo will be responsible for all clinical development and commercialization. Endo will also provide research funding and milestone payments and receive worldwide rights to all intellectual property that results from this collaboration.
To comment on this story, go to BLOGbiotech.